Literature DB >> 19282104

Lack of KRAS and BRAF mutation in renal cell carcinoma.

S Gattenlöhner, B Etschmann, H Riedmiller, H-K Müller-Hermelink.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19282104     DOI： 10.1016/j.eururo.2009.02.024

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  15 in total

1.  BRAF mutations in metanephric adenoma of the kidney.

Authors:  Toni K Choueiri; John Cheville; Emanuele Palescandolo; André P Fay; Philip W Kantoff; Michael B Atkins; Jesse K McKenney; Victoria Brown; Megan E Lampron; Ming Zhou; Michelle S Hirsch; Sabina Signoretti
Journal:  Eur Urol       Date:  2012-06-09       Impact factor: 20.096

Review 2.  Inhibition of Ras for cancer treatment: the search continues.

Authors:  Antonio T Baines; Dapeng Xu; Channing J Der
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

3.  Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma.

Authors:  Gregory W Hosier; Matthew T Roberts
Journal:  Can Urol Assoc J       Date:  2016-09-13       Impact factor: 1.862

4.  KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.

Authors:  D P Modest; P Camaj; V Heinemann; B Schwarz; A Jung; R P Laubender; S Gamba; C Haertl; S Stintzing; S Primo; C J Bruns
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-02       Impact factor: 4.553

Review 5.  TRAIL-mediated signaling in prostate, bladder and renal cancer.

Authors:  Christina Voelkel-Johnson
Journal:  Nat Rev Urol       Date:  2011-06-14       Impact factor: 14.432

Review 6.  mTOR inhibitors in advanced renal cell carcinoma.

Authors:  Martin H Voss; Ana M Molina; Robert J Motzer
Journal:  Hematol Oncol Clin North Am       Date:  2011-08       Impact factor: 3.722

7.  Implication of RAF and RKIP genes in urinary bladder cancer.

Authors:  Apostolos Zaravinos; Maria Chatziioannou; George I Lambrou; Ioannis Boulalas; Dimitris Delakas; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2010-09-18       Impact factor: 3.201

8.  Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia.

Authors:  Yangsook Song Green; Timothy Sargis; Ethan Conrad Reichert; Eleanor Rudasi; Daniel Fuja; Eric Jonasch; Mei Yee Koh
Journal:  Mol Cancer Res       Date:  2019-01-31       Impact factor: 5.852

9.  Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma.

Authors:  Aaron M Udager; Jincheng Pan; Martin J Magers; Ganesh S Palapattu; Todd M Morgan; Jeffrey S Montgomery; Alon Z Weizer; Khaled S Hafez; David C Miller; James S Wolf; Jonathan B McHugh; Arul M Chinnaiyan; Saravana M Dhanasekaran; Rohit Mehra
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

10.  Appearance of malignant melanoma after a non-cutaneous cancer diagnosis.

Authors:  Ugo Bottoni; Rita Clerico; Giovanni Paolino; Marina Ambrifi; Cecilia Luci; Paola Corsetti; Stefano Calvieri
Journal:  Ecancermedicalscience       Date:  2013-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.